SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 134 filers reported holding SAGE THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,443,721 | -73.2% | 313,106 | -38.8% | 0.00% | -80.0% |
| Q2 2023 | $24,072,594 | -39.4% | 511,965 | -45.9% | 0.01% | -37.5% |
| Q1 2023 | $39,699,951 | +10.0% | 946,138 | +0.0% | 0.01% | 0.0% |
| Q4 2022 | $36,084,864 | -17.1% | 946,116 | -14.9% | 0.01% | -20.0% |
| Q3 2022 | $43,527,000 | +21.8% | 1,111,522 | +0.5% | 0.01% | +25.0% |
| Q2 2022 | $35,733,000 | +244.4% | 1,106,276 | +252.9% | 0.01% | +300.0% |
| Q1 2022 | $10,376,000 | -46.1% | 313,457 | -30.8% | 0.00% | -50.0% |
| Q4 2021 | $19,268,000 | -8.0% | 452,959 | -4.1% | 0.00% | 0.0% |
| Q3 2021 | $20,936,000 | -27.4% | 472,494 | -6.9% | 0.00% | -33.3% |
| Q2 2021 | $28,831,000 | -19.2% | 507,506 | +6.4% | 0.01% | -33.3% |
| Q1 2021 | $35,697,000 | -38.0% | 476,907 | -28.4% | 0.01% | -40.0% |
| Q4 2020 | $57,603,000 | +76.7% | 665,860 | +24.9% | 0.02% | +66.7% |
| Q3 2020 | $32,591,000 | -3.6% | 533,235 | -34.4% | 0.01% | -10.0% |
| Q2 2020 | $33,795,000 | +41.6% | 812,785 | -2.2% | 0.01% | +11.1% |
| Q1 2020 | $23,871,000 | -37.0% | 831,188 | +58.3% | 0.01% | 0.0% |
| Q4 2019 | $37,906,000 | -18.3% | 525,092 | +58.9% | 0.01% | -30.8% |
| Q3 2019 | $46,374,000 | -25.5% | 330,558 | -2.8% | 0.01% | -27.8% |
| Q2 2019 | $62,252,000 | +19.7% | 340,006 | +4.0% | 0.02% | +12.5% |
| Q1 2019 | $52,020,000 | +103.5% | 327,064 | +22.6% | 0.02% | +100.0% |
| Q4 2018 | $25,557,000 | -19.3% | 266,804 | +19.0% | 0.01% | 0.0% |
| Q3 2018 | $31,660,000 | -52.2% | 224,143 | -47.0% | 0.01% | -55.6% |
| Q2 2018 | $66,199,000 | +26.6% | 422,915 | +30.2% | 0.02% | +38.5% |
| Q1 2018 | $52,301,000 | -4.3% | 324,709 | -2.1% | 0.01% | 0.0% |
| Q4 2017 | $54,637,000 | +58.0% | 331,719 | -40.2% | 0.01% | +44.4% |
| Q3 2017 | $34,581,000 | -60.9% | 555,078 | -50.0% | 0.01% | -60.9% |
| Q2 2017 | $88,435,000 | +668.7% | 1,110,430 | +586.0% | 0.02% | +666.7% |
| Q1 2017 | $11,504,000 | +46.4% | 161,867 | +5.2% | 0.00% | +50.0% |
| Q4 2016 | $7,859,000 | -45.2% | 153,927 | -50.6% | 0.00% | -50.0% |
| Q3 2016 | $14,343,000 | +66.7% | 311,480 | +9.1% | 0.00% | +100.0% |
| Q2 2016 | $8,604,000 | +107.5% | 285,581 | +120.8% | 0.00% | 0.0% |
| Q1 2016 | $4,146,000 | -60.9% | 129,324 | -28.9% | 0.00% | -50.0% |
| Q4 2015 | $10,605,000 | +65.3% | 181,911 | +20.0% | 0.00% | +300.0% |
| Q3 2015 | $6,415,000 | +160.1% | 151,582 | +348.7% | 0.00% | 0.0% |
| Q2 2015 | $2,466,000 | +949.4% | 33,779 | +621.6% | 0.00% | – |
| Q1 2015 | $235,000 | -81.1% | 4,681 | -86.3% | 0.00% | – |
| Q4 2014 | $1,246,000 | -31.9% | 34,054 | -41.4% | 0.00% | -100.0% |
| Q3 2014 | $1,831,000 | – | 58,136 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |